8-K: Premier Inc. Reports Q1 FY26 Results Amidst Pending Acquisition

Premier, Inc. reported a 3% decrease in total net revenue and a significant drop in GAAP net income for Q1 FY2026, while withdrawing future guidance due to its pending acquisition by Patient Square Capital.

Summary

• Total net revenue for the fiscal-year 2026 first quarter was $240.0 million, a 3% decrease from the prior-year period.
• GAAP net income from continuing operations was $15.3 million, or $0.21 per fully diluted share, a 79% decrease from $72.9 million in the prior-year period, which included a $57.0 million non-operating gain from a derivative lawsuit settlement.
• Adjusted EBITDA decreased 12% to $55.0 million from $62.4 million in the prior-year period.
• Adjusted EPS was $0.30, a 12% decrease from $0.34 in the prior-year period.
• The company has withdrawn its fiscal-year 2026 guidance due to the pending acquisition by an affiliate of Patient Square Capital, LP.
• Premier has suspended the declaration and distribution of common stock dividends in future quarters due to the pending acquisition.
• The S2S Global direct sourcing business was divested on October 1, 2024.
• Efforts to wind down the remaining components of the Contigo Health business are ongoing and expected to be substantially complete by December 31, 2025.
• Net cash provided by operating activities from continuing operations decreased to $15.9 million from $80.0 million in the prior-year period.
• Non-GAAP free cash flow was $(14.0) million, compared to $16.2 million in the prior-year period.

Sentiment

Score: 3

Explanation: The financial results show significant declines across key metrics (revenue, net income, EBITDA, EPS, cash flow), indicating a challenging quarter. While the prior year's GAAP net income included a one-time gain, adjusted metrics also show substantial decreases. The pending acquisition and withdrawal of guidance introduce uncertainty, though the acquisition itself could be seen as a strategic positive for long-term value.

Positives

• Software licenses, other services and support revenue increased 5% to $19.7 million, driven by growth in supply chain co-management and digital supply chain solutions.
• The company completed its $800.0 million share repurchase authorization by August 2025, including a $200.0 million accelerated share repurchase program.

Negatives

• Total net revenue decreased 3% to $240.0 million.
• GAAP net income from continuing operations decreased 79% to $15.3 million, largely due to a non-recurring gain in the prior year.
• GAAP diluted EPS from continuing operations decreased 71% to $0.21.
• Adjusted EBITDA decreased 12% to $55.0 million.
• Adjusted net income decreased 28% to $25.1 million.
• Adjusted EPS decreased 12% to $0.30.
• Performance Services segment net revenue decreased 9% to $87.9 million, primarily due to lower license revenue.
• Performance Services segment adjusted EBITDA decreased 29% to $10.6 million.
• Cash and cash equivalents decreased to $43.4 million from $83.7 million at June 30, 2025.
• Net cash provided by operating activities from continuing operations decreased significantly to $15.9 million from $80.0 million.
• Non-GAAP free cash flow was negative $(14.0) million.

Risks

• Inability to consummate the Merger with Patient Square Capital within the anticipated time period, or at all, due to failure to obtain required regulatory approvals, stockholder approval, or complete financing arrangements.
• Adverse effects on the market price of common stock from announcements relating to the Merger.
• Disruption from the Merger making it more difficult to maintain business and operational relationships, including retaining and hiring key personnel and maintaining relationships with members, customers, and vendors.
• The occurrence of any event, change, or other circumstances that could give rise to the termination of the Merger agreement.
• Risks related to disruption of current plans and operations or the diversion of management's attention from ongoing business operations due to the Merger.
• Significant transaction costs associated with the Merger.
• Risk of litigation and/or regulatory actions related to the Merger or unfavorable results from currently pending or future litigation and proceedings.

Future Outlook

Premier has withdrawn its previously issued fiscal-year 2026 guidance due to the pending acquisition by Patient Square Capital. The company expects the remaining components of the Contigo Health business to be substantially wound down by December 31, 2025.

Management Comments

• Premier, Inc. reported financial results for the fiscal-year 2026 first quarter ended September 30, 2025.
• The company's efforts to wind down the remaining components of the Contigo Health business remain ongoing, with an expected substantial wind-down by December 31, 2025.
• The company has suspended the declaration and distribution of common stock dividends in future quarters as a result of the pending acquisition by Patient Square Capital.

Industry Context

The healthcare industry continues to evolve rapidly, with companies like Premier playing a critical role in uniting providers, suppliers, and payers. Premier's focus on technology-driven healthcare improvement, including supply chain solutions and data analytics, aligns with broader industry trends towards efficiency and digital transformation. However, the reported declines in revenue and profitability, particularly in Performance Services, suggest challenges in certain segments, potentially reflecting competitive pressures or shifts in client demand. The pending acquisition by Patient Square Capital indicates a significant strategic shift, potentially aiming to leverage private equity resources for further transformation or market consolidation within the healthcare improvement sector.

Legal Proceedings

• Risk of litigation and/or regulatory actions related to the pending Merger or unfavorable results from currently pending litigation and proceedings or litigation and proceedings that could arise in the future.

Stakeholder Impact

• Shareholders: Suspension of future common stock dividends and the pending acquisition will significantly impact shareholder value and investment strategy. The market price of common stock could be adversely affected by Merger announcements or termination risks.
• Employees: Disruption from the Merger could make it more difficult to retain and hire key personnel.
• Customers/Members/Vendors: Disruption from the Merger could make it more difficult to maintain business and operational relationships.
• Creditors: Increased interest expense due to higher borrowings on the Credit Facility could impact the company's financial health, though the pending acquisition may alter the debt structure.

Next Steps

• Completion of the pending acquisition by Patient Square Capital, LP, subject to regulatory approvals and stockholder approval.
• Substantial wind-down of the remaining components of the Contigo Health business by December 31, 2025.
• Filing of the Form 10-Q for the quarter ended September 30, 2025, with the SEC shortly after the release date.

Key Dates

Recommendation

The company's financial performance for Q1 FY2026 shows significant declines across most key metrics, including revenue, adjusted EBITDA, and free cash flow. However, the primary driver for investment decisions at this juncture is the pending acquisition by Patient Square Capital. With guidance withdrawn and dividends suspended, the stock's valuation will largely be tied to the acquisition terms and the likelihood of its completion. For existing shareholders, holding is advisable to realize the acquisition value, assuming the deal closes as expected. For new investors, the upside is capped by the acquisition price, and the downside is limited by the deal's floor, making it a 'hold' rather than a 'buy' or 'sell' based on fundamental performance alone.

Keywords

Healthcare improvement, Supply chain services, Performance services, Healthcare technology, Patient Square Capital, Acquisition, Financial results, Q1 FY2026, PINC, SEC filing